Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...
The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...
From now to Dec 31st, 2025, we’re offering a free pilot trail on HTP antibody production for new clients to accelerate your ...
The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein ...
AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise ...
In this GEN webinar, a distinguished panel of experts discuss next-generation expression systems, optimized screening methods, and integrated development strategies that are enabling higher-performing ...
Antibody engineering enables the generation of novel and diverse antibody constructs. The development of therapeutic antibodies is highly dependent on antibody engineering, whether for the generation ...
Supported by a grant (1R01HL166246, to Dr. Bendapudi) from the National Institutes of Health and by the Luick Family Fund of the Department of Pathology at Massachusetts General Hospital. Disclosure ...
The cost-effective, easy-to-use T7 expression system has been integral to Escherichia coli protein production since its introduction in 1986. Now, a just-developed enhancement is making it even better ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback